This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial

This study has been completed.
Information provided by:
GWT-TUD GmbH Identifier:
First received: February 22, 2008
Last updated: March 5, 2008
Last verified: March 2008

The aim of the study was to analyse the independent and joint effects of the components of the metabolic syndrome (MetS) on the incidence of diabetes in people with impaired glucose tolerance (IGT) and to assess the effect of acarbose by MetS status.

Double-blind placebo controlled trial, 1,368 patients, follow-up time 3.3 years. MetS by ATP III definition with fasting plasma glucose of ≥ 6.1 mmol/l as limit for impaired fasting glucose (IFG).

Condition Intervention Phase
Metabolic Syndrome Drug: acarbose Drug: placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: Metabolic Syndrome and Its Single Traits as Risk Factors of Diabetes in People With Impaired Glucose Tolerance: The STOP-NIDDM Trial

Resource links provided by NLM:

Further study details as provided by GWT-TUD GmbH:

Primary Outcome Measures:
  • Incidence of newly diagnosed type 2 diabetes

Secondary Outcome Measures:
  • newly diagnosed hypertension

Estimated Enrollment: 1429
Arms Assigned Interventions
Active Comparator: 1 Drug: acarbose
Placebo Comparator: 2 Drug: placebo


Ages Eligible for Study:   40 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • High risk population
  • Age 40 to 70 yrs.
  • BMI > 25 and < 40; FPG >5.5 mmol/l and < 7.8 mmol/l; IGT in OGGT

Exclusion Criteria:

  • Known type 2 diabetes
  • Drug intake affecting glucose tolerance
  • Any cardiovascular events within the last 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00629213

Dresden, Saxony, Germany, 01187
Sponsors and Collaborators
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00629213     History of Changes
Other Study ID Numbers: Canadian: ACRI02; Bay g 5421
Study First Received: February 22, 2008
Last Updated: March 5, 2008

Keywords provided by GWT-TUD GmbH:
type 2 diabetes,
metabolic syndrome,
acarbose treatment

Additional relevant MeSH terms:
Metabolic Syndrome X
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Glycoside Hydrolase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on September 21, 2017